EMEA-003314-PIP01-22 - paediatric investigation plan

Influenza recombinant H7 haemagglutinin

Key facts

• Active Substance:
  Influenza recombinant H7 haemagglutinin
• Therapeutic area:
  Vaccines
• Decision number:
  P/0283/2023
• PIP number:
  EMEA-003314-PIP01-22
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Prevention of influenza infection
• Route(s) of administration:
  Intramuscular use
• Contact for public enquiries:

  Sanofi Pasteur

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  14/07/2023

Decision

P/0283/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for influenza recombinant H7 haemagglutinin (EMEA-003314-PIP01-22)

Reference Number: EMA/317156/2023